Below is some other the on-going Phase II-III Clinical Trials which are being managed by Info Kinetics.
If you are a patient and have interest in participating in these clinical trials, please feel free to contact us for further details (participate@info-kinetics.com)
A Randomized, Open-Label, Multicentre, Phase 3 Study of Epoetin Alfa plus Standard Supportive Care versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy. (EPO-ANE-3010)
What is this study about?
Anemia is a common complication of the treatment of metastatic breast cancer and it related to the effects of chemotherapy and to chronic disease itself. The purpose of this study is to examine the safety and impact on tumor progression of epoetin afla plus standard supportive care (packed red blood cell transfusions) versus standard supportive care alone, when used to treat anemia according to label guidance. This study will be done in patients with metastatic breast cancer with anemic receiving first-line or second-line standard chemotherapy.
Who is eligible?
Metastatic breast cancer patients with anemic receiving first-line or second-line standard chemotherapy
An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in “triple negative” breast cancer. (Beatrice study, BO20289)
What is this study about?
This 2 arm open-label study will evaluate the efficacy and safety of the addition of Avastin (bevacizumab) to standard adjuvant therapy in patients with triple negative breast cancer. Patients will be randomized to receive either standard chemotherapy (anthracycline +/- taxane or taxane only), or standard chemotherapy given concurrently with 1 year of Avastin.
Who is eligible?
Patients with operable primary invasive breast cancer, completed definitive local-regional surgery and primary tumor confirmed as triple negative.
A phase II Biomarker Identification Trial for Erlotinib (Tarcevaâ) in Patients with Advance Pancreatic Carcinoma. (MARK study BO21129)
What is this study about?
This study is designed to identify biomarkers which may predict improvement in progression free survival from treatment with Tarceva, in patients with advanced pancreatic cancer who failed one prior regimen of standard chemotherapy or who are deemed unsuitable for chemotherapy. It will also assess the efficacy and safety of Tarceva in this patient population. Patients will be randomized to receive either Tarceva placebo daily. Tumor tissue will be used for biomarker analysis.
Who is eligible?
Patients with metastatic pancreatic cancer who failed at least one prior chemotherapy regimen or deemed unsuitable for chemotherapy.
A Randomized, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant (26866138-LYM-3002)
What is this study about?
Mantle cell lymphoma is an incurable subtype of non-Hodgkin’s lymphoma that was recognized as a unique clinicopathologic entity in the 1990’s. This study is to compare the efficacy and safety of two chemotherapy regimen (VcR-CAP versus R-CHOP) in patients who have newly diagnosed mantle cell lymphoma stage II, III or IV and who are ineligible to undergo bone marrow transplantation, as assessed by significant prolongation of progression free survival.
Who is eligible?
Patients who are diagnosed with Mantle Cell Lymphoma (stage II, III or IV) with at least 1 measurable disease and not eligible for bone marrow transplantation as assessed by treating clinician.
A Multinational, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy (SAVE-ONCO, EFC 6521)
What is this study about?
This study is to compare the efficacy of AVE5026 versus placebo in the prevention of VTE in cancer patients at high risk for VTE and who are undergoing chemotherapy. The secondary objectives are to evaluate the safety of AVE5026, to document AVE5026 exposures, to try identifying a metagene predictor of VTE and to assess the survival status at one year in this population.
Who is eligible?
Cancer patients with metastatic or locally advanced solid tumor of lung, pancreas, stomach, colon/rectum, bladder or ovary, who are at risk for VTE and receiving a (new) course of chemotherapy with a minimum intent of 3 months therapy.
Efficacy and tolerability of EPs® 7630 film-coated tablets in patients (≥ 18 years old) with acute rhinopharyngitis (701004.01.009)
What is this study about?
The acute inflammation of nose and throat regions (acute rhinopharyngitis) with symptoms such as nasal congestion, runny nose, sore throat and headache, is one of the most common illnesses worldwide. Though mostly caused by viruses, these infections are often treated unnecessarily with antibiotics in the beginning stages. Therefore, alternative therapy concepts, e.g. therapy with herbals are desired both by doctors and patients. Purpose of this study is to determine whether EPs® 7630 film-coated tablets possess a beneficial effect in the therapy of acute rhinopharyngitis (inflammation of nose and throat), as well as the safety and tolerability.
Who is eligible?
Those who have symptoms (such as nasal discharge, sore throat, sneezing, nasal congestion, scratchy throat, hoarseness , cough, headache, or fever) for less than 72 hours and NOT on any medication.
A randomized, double blind, controlled study on the effect of a Growing up milk on the occurrence of infections in toddlers (Tod.1.C/D)
What is this study about?
In many countries, infants and young children often attend daycare centres. It has been well documented that daycare attendance increases the risk of infections especially respiratory infections and gastrointestinal infections. The purpose of this study is to investigator the effect of a renewed formula milk on the occurrence of infections in healthy toddlers attending daycare centres.
Who is eligible?
Children aged between 13 to 29 months old who attend daycare centres (with > 20 children in total) at least 2 times a week.
